|
|
Article: Possible increased risk of ovarian cancer with fertility drugs.
- Article from:
- FDA Consumer
- Article date:
- April 1, 1993
CopyrightCOPYRIGHT 1993 U.S. Government Printing Office. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
At FDA's request, drug firms are revising fertility drug labels to include ovarian cancer as a potential adverse drug reaction.
FDA acted last January in response to recent data indicating that use of these drugs may have a stronger association with the disease in women who have never been pregnant than previously believed.
Since fertility drugs were first marketed, at least 12.5 million courses of the drugs have been prescribed in the United States to women unable to conceive. (FDA approved Clomid [clomiphene citrate] in 1967 and Perganol [menotropins] in 1974.) In that time, FDA has received reports of six cases of ovarian cancer associated with their ...